Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

A continuing education article for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians The purpose of this article is to provide advanced practitioners with important information about new treatment options for mantle cell lymphoma and chronic lymphocytic leukemia, including novel oral agents, management of related side effects, and patient education. The activity's target audience will consist of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians. After completing this educational activity, participants should be able to: 1. Identify clinical features and considerations to determine which patients are eligible for treatment with ibrutinib 2. Recognize potential side effects and adverse events associated with ibrutinib and intervene to prevent, assess, and/or manage them appropriately should they occur Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit. Physicians. The Meniscus Educational Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Meniscus Educational Institute designates this journal article for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Pharmacists. The knowledge-based accredited education lectures are intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to this program, for 0.50 contact hours, is 0429-9999-15-015-H01-P. All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Meniscus Educational Institute has identified and resolved all conflicts of interest in accordance with the MEI policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity. has acted as a consultant and served on speakers bureuas for Pharmacyclics. PLANNERS Jeannine Coronna has nothing to disclose. Claudine Kiffer has nothing to disclose. Lynn Rubin has nothing to disclose. Disclaimer This activity has been designed to provide continuing education that is focused …